Sanjay Shrivastava 0:04
Inova vascular is based here in Southern California, and my name is Sanjay Srivastava. I'm the founder and CEO of the company. I've been doing this, what I call in the body plumbing business, for a long time, 25 years or so, and many of the friends that have worked with me in the past or other known faces. The theme of the company is that you stick a needle at the groin and using blood vessels as pathways fix a problem, generally a body plumbing problem. So every three to five years, I take and work in one subset of the space, and then after developing and commercializing, I've had the privilege to just move on to a different part of the body and keep doing somewhat of a similar similar things. So the problem that ANOVA is addressing is that of a clot that forms, the undesirable clot that forms in the body, and typically it forms in legs, that gives a condition called Deep vein thrombosis, or DVT, that you may have heard of, and that occurs for a variety of genetic, environmental and personal factors. It can be symptomatic. DVT can be symptomatic, or it may not be, depending on the situation, but then when clot gets dislodged from these veins and legs, it actually ends up in lungs. And when it ends up in artery in lungs called pulmonary artery, then it gives a condition called pulmonary embolism, which is not only symptomatic right away, meaning you have symptoms similar to that of having a heart attack, breathing difficulty, chest pain, but it's also very dangerous, meaning the mortality is very, very high in it. So patient goes to the emergency room right away and gets admitted into ICU when you have PE so now, those of you who follow the cardiovascular intervention, you are probably aware that about 10 years ago, there was a very successful demonstration of removing clot in a condition, an acute schemic stroke from brain through similar axis of drawing. And by 2000 and I happen to be leading one of the devices R and D from 2007 to 2011 that became a major disruption in the field. By 2015 and 16, there were a lot of people working in stroke. And that's when I started to think about, what else can I do? And this company is about two, two and a half years old. Now we have FDA cleared products. I'll talk about the technology in a minute, but little more on the on the and I'll make a linkage on on why I'm talking about stroke, and what the connection is here, there's about a million people that get that get the venous thromboembolism, the disease that I'm talking about, each year in the US alone, about 600,000 of those end up in PE or pulmonary embolism, leading to about 100,000 deaths in the US. Now, there is no good treatment. There's up until few years ago, they weren't even diagnosed well, but luckily, with the efforts of many of the doctors and a few companies that have come up in the space now there's there's increasingly better diagnostics in the hospitals, and there's about 40,000 of the 600,000 PES that undergo the catheter based treatment that I'm talking about market that also makes it a very attractive market. So we're about a billion and a half dollar market for just for intervention alone, in back to me alone, and that's going to go to about $3 billion market. So it's a pretty attractive sort of growth. One of the I'd submit to you that one of the most attractive spaces within cardiovascular intervention. I know everybody is thinking of tricuspid and mitral valves and electrophysiology, et cetera, but considering that this is in and out, so it's not a PMA, these are the products that you can get approved with relatively simple clinical studies, it's a very attractive space. So deriving the inspiration from very, very successful treatments in acute schemic stroke, where you can go on a with a catheter based treatment from groin. You could through groin, you could remove the clot. We We started to create similar solutions for PE and DVT. And our solutions are the set of now FDA cleared products called Malibu aspiration catheter and Laguna clot retriever. And there's two companies that already have products in the space, and both are huge, huge success. What we view those to be the initial products, and there is plenty of opportunities to make the treatments better so it can be used by more doctors. It can be done faster and it can be done better, and that's what we have done. We have four sizes of aspiration catheters, two sizes of clot retrievers.
© 2024 Life Science Intelligence, Inc., All Rights Reserved.
